Markers of T-cell dysfunction and not inflammaging predict the waning of humoral responses to SARS-CoV-2 mRNA booster vaccination in people with HIV

Matteo Augello; Valeria Bono; Roberta Rovito; Andrea Santoro; Camilla Tincati; Giulia Marchetti

doi:10.1097/QAD.0000000000004010

Markers of T-cell dysfunction and not inflammaging predict the waning of humoral responses to SARS-CoV-2 mRNA booster vaccination in people with HIV

AIDS. 2024 Nov 15;38(14):1987-1990. doi: 10.1097/QAD.0000000000004010. Epub 2024 Oct 31.

Authors

Matteo Augello¹, Valeria Bono, Roberta Rovito, Andrea Santoro, Camilla Tincati, Giulia Marchetti

Affiliation

¹ Clinic of Infectious Diseases and Tropical Medicine, San Paolo Hospital, ASST Santi Paolo e Carlo, Department of Health Sciences, University of Milan, Milan, Italy.

PMID: 39474654
DOI: 10.1097/QAD.0000000000004010

Abstract

In this prospective longitudinal study, we evaluated the durability of humoral responses to SARS-CoV-2 mRNA booster vaccination in 93 people with HIV, exploring the possible role of T-cell dysfunction and inflammaging biomarkers in predicting antibody waning. We found that, despite a negligible influence of the inflammaging milieu, low CD4/CD8 ratio and CD4+CD127+ percentage as well as high CD8+CD38+CD45RO+ percentage are associated with faster antibody waning, in turn contributing to our understanding of the determinants of COVID-19 vaccine-elicited immune response in this population.

MeSH terms

Adult
Antibodies, Viral* / blood
Biomarkers / blood
CD4-CD8 Ratio
COVID-19 Vaccines* / administration & dosage
COVID-19 Vaccines* / immunology
COVID-19* / immunology
COVID-19* / prevention & control
Female
HIV Infections* / immunology
Humans
Immunity, Humoral
Immunization, Secondary*
Longitudinal Studies
Male
Middle Aged
Prospective Studies
SARS-CoV-2 / immunology
T-Lymphocytes / immunology

Substances

COVID-19 Vaccines
Antibodies, Viral
Biomarkers